Azoxime bromide (Azoximeri bromidum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Other immunomodulators

Included in the formulation
  • Polyoxidonium®
    lyophilizate locally w / m in / in 
    NPO PETROVAKS PHARM, LLC     Russia
  • Polyoxidonium®
    suppositories rect. the vagina. 
    NPO PETROVAKS PHARM, LLC     Russia
  • Polyoxidonium®
    pills inwards 
    NPO PETROVAKS PHARM, LLC     Russia
  • Polyoxidonium®
    suppositories rect. the vagina. 
    NPO PETROVAKS PHARM, LLC     Russia
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    L.03.A.X   Other immunostimulants

    Pharmacodynamics:

    It has a direct effect on natural killers and phagocytic cells, stimulates the formation of antibodies. Increases immunity against generalized and local infections caused by bacteria, viruses or fungi.

    Azoximer bromide restores immunity to secondary immunodeficiency states caused by various infections, traumas, burns, autoimmune diseases, malignant tumors, complications after surgical operations, the use of chemotherapeutic agents, cytostatics, steroid hormones.

    With sublingual administration, the drug activates lymphoid cells located in the bronchi, nasal cavity, eustachian tubes, which results in an increase in the resistance of these organs to infectious agents.

    When administered orally, the drug activates lymphoid cells in the intestine, namely B cells that produce secretory IgA.

    Along with immunomodulating action azoxime bromide has a pronounced detoxification and antioxidant activity, has the ability to excrete toxins from the body, salts of heavy metals, inhibits lipid peroxidation, increases the resistance of cell membranes to cytotoxic action, reduces the toxicity of drugs with simultaneous administration. These properties are determined by the structure and high molecular weight nature of the azoxime bromide.

    Pharmacokinetics:

    Bioavailability with intramuscular injection is 89%. After intramuscular injection, the time to reach Cmax in blood plasma is 40 minutes. Quickly distributed in all organs and tissues. With rectal administration, bioavailability is at least 70%. Cmax in blood plasma after rectal administration is achieved after 1 hour. The half-distribution period is about 30 minutes. In organism azoxime bromide hydrolyzed to oligomers, which are excreted mainly by the kidneys. Half-life (slow phase) is 36.2 hours.

    After oral administration azoxime bromide quickly absorbed from the digestive tract, bioavailability is approximately 50%. Cmax in blood plasma is achieved 3 hours after ingestion. Azoxime bromide is a hydrophilic compound. Apparent Vd is about 0.5 l / kg, which indicates that the drug is distributed mainly in the intercellular fluid. The half-absorption period is 35 minutes. In the body it is hydrolyzed to oligomers, which are excreted mainly by the kidneys. There is no cumulative effect. Half-life - 18 hours.

    Indications:

    Complex treatment of diseases accompanied by suppression of immunity: purulent-septic diseases; acute and chronic viral and bacterial infections; prostatitis, urethritis, chronic pyelonephritis, cystitis; chronic salpingoophoritis, endometritis, colpitis (bacterial and nonspecific); ectopia of the vaginal part of the cervix, dysplasia of the cervix, leukoplakia of traumatic and viral etiology; suppression of immunity and hematopoiesis after radiation therapy and chemotherapy in patients with oncological diseases; activation of regenerative processes (fractures,burns, necrosis); prevention of infectious complications in surgical patients.

    Chronical bronchitis.

    Recurrent furunculosis.

    ICD-10

    I.A15-A19.A15   Tuberculosis of respiratory organs, confirmed bacteriologically and histologically

    I.A15-A19.A16.9   Tuberculosis of respiratory organs, unspecified, without mention of bacteriological or histological confirmation

    I.A15-A19.A18   Tuberculosis of other organs

    I.A50-A64.A56.0   Chlamydial infections of the lower parts of the genito-urinary tract

    I.A50-A64.A56.1   Chlamydial infections of the pelvic organs and other urogenital organs

    I.A50-A64.A60   Anogenital herpetic viral infection [herpes simplex]

    I.B00-B09.B00   Infections caused by the herpes simplex virus [herpes simplex]

    I.B95-B97.B97.7   Papillomaviruses as a cause of diseases classified elsewhere

    I.B99.B99   Other and unspecified infectious diseases

    III.D80-D89.D84.9   Immunodeficiency, unspecified

    VIII.H65-H75.H66   Purulent and unspecified otitis media

    VIII.H65-H75.H74.9   Disease of middle ear and mastoid process, unspecified

    VIII.H80-H83.H83.9   Disease of inner ear, unspecified

    IX.I80-I89.I83.2   Varicose veins of the lower extremities with ulcer and inflammation

    X.J00-J06.J00   Acute nasopharyngitis (runny nose)

    X.J00-J06.J01   Acute Sinusitis

    X.J00-J06.J02   Acute pharyngitis

    X.J00-J06.J03   Acute tonsillitis

    X.J00-J06.J04   Acute laryngitis and tracheitis

    X.J00-J06   Acute respiratory infections of the upper respiratory tract

    X.J00-J06.J06.9   Acute upper respiratory tract infection, unspecified

    X.J10-J18.J10   Influenza caused by an identified influenza virus

    X.J10-J18.J11   Influenza, virus not identified

    X.J30-J39.J30   Vasomotor and allergic rhinitis

    X.J30-J39.J31   Chronic rhinitis, nasopharyngitis and pharyngitis

    X.J30-J39.J32   Chronic Sinusitis

    X.J30-J39.J35   Chronic diseases of the tonsils and adenoids

    X.J30-J39.J35.0   Chronic tonsillitis

    X.J30-J39.J37   Chronic laryngitis and laryngotracheitis

    X.J40-J47.J45   Asthma

    XI.K00-K14.K13.7   Other and unspecified lesions of the oral mucosa

    XI.K55-K63   Other bowel diseases

    XI.K55-K63.K63.8   Other specified intestinal diseases

    XII.L20-L30.L20   Atopic dermatitis

    XII.L20-L30.L20.8   Other atopic dermatitis

    XII.L20-L30.L28.0   Simple chronic lichen

    XII.L20-L30.L30.3   Infectious dermatitis

    XII.L80-L99.L98.4   Chronic skin ulcer, not elsewhere classified

    XIII.M05-M14.M05   Seropositive rheumatoid arthritis

    XIII.M05-M14.M06.9   Rheumatoid arthritis, unspecified

    XIV.N10-N16.N10   Acute tubulointerstitial nephritis

    XIV.N10-N16.N11   Chronic tubulointerstitial nephritis

    XIV.N30-N39.N30   Cystitis

    XIV.N30-N39.N34   Urethritis and urethral syndrome

    XIV.N40-N51.N41   Inflammatory diseases of the prostate

    XIV.N40-N51.N45   Orchitis and epididymitis

    XIV.N40-N51.N49   Inflammatory diseases of male genital organs, not elsewhere classified

    XIV.N70-N77   Inflammatory diseases of female pelvic organs

    XIV.N70-N77.N70   Salpingitis and oophoritis

    XIV.N70-N77.N70.1   Chronic salpingitis and oophoritis

    XIV.N70-N77.N71   Inflammatory diseases of the uterus, except the cervix

    XIV.N70-N77.N72   Inflammatory disease of the cervix

    XIV.N70-N77.N76   Other inflammatory diseases of the vagina and vulva

    XIV.N80-N98.N86   Erosion and ectropion of the cervix

    XIV.N80-N98.N87   Cervical dysplasia

    XIV.N80-N98.N88.0   Cervical leukoplakia

    XIV.N80-N98.N89.3   Vaginal dysplasia, unspecified

    XIV.N80-N98.N89.4   Leukoplakia of the vagina

    XVIII.R50-R69.R54   Old age

    XIX.T08-T14.T14   Injury of unspecified site

    XIX.T20-T32.T30   Thermal and chemical burns, unspecified

    XX.Y40-Y59   Medicinal products, medicines and biological substances that cause adverse reactions during therapeutic use

    XX.Y83-Y84.Y84.2   Radiological procedure and radiation therapy

    XXI.Z20-Z29.Z29.8   Other specified preventive measures

    XXI.Z40-Z54.Z50.9   Treatment, including a rehabilitation procedure, unspecified

    XXI.Z40-Z54.Z51.0   Radiotherapy course (supportive)

    XXI.Z40-Z54.Z51.1   Chemotherapy for neoplasm

    Contraindications:

    Pregnancy and lactation.

    Hypersensitivity.

    Age before 12 years.

    Carefully:

    Liver diseases, age up to 6 months with intranasal and sublingual application, acute renal failure.

    Pregnancy and lactation:

    Category FDA not determined. Not recommended for use in pregnancy and lactation.

    Dosing and Administration:

    Rectal / intravaginal: 0.1-0.2 mg / kg at night 1 time per day (it is necessary to clean the intestine first). The course of treatment - 9 suppositories. After 3-4 months you can repeat the course.

    Subcutaneously: 6-12 mg once a day, the course of treatment is 5-10 injections.

    Liofilizate for the preparation of solution for injection and topical application. Intramuscularly, intravenously drip, adults 6-12 mg per dayki once (every day, every other day or 1-2 times a week), children from 6 months to 0.1-0.15 mg / kg after 48-72 hours. The course of treatment is 5-7 injections.

    Sublingually / orally or intranasal: adults - 12-24 mg, adolescents - 12 mg daily. Take 1-3 times a day, depending on the indications.

    Side effects:

    Soreness at the injection site.

    Overdose:

    Not described, treatment is symptomatic.

    Interaction:

    Not described.

    Special instructions:

    During the administration of the drug, peripheral blood monitoring is recommended.

    Impact on the ability to drive vehicles and manage mechanisms

    Not found.

    Instructions
    Up